To include your compound in the COVID-19 Resource Center, submit it here.

Tolerion reports Phase II data for Type I diabetes vaccine

Tolerion Inc. (Portola Valley, Calif.) said all doses of once-weekly intramuscular TOL-3021 for 12 weeks improved C-peptide levels, a marker of

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE